Amyloid plaque load analysis in triple-mutant mouse brains

Exploratory Score: 0.880 Price: $0.50 Alzheimer's disease APP/PSEN1/GD3S-/- triple-transgenic mouse brains Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting St8sia1 in APP/PSEN1/GD3S-/- triple-transgenic mouse brains. Primary outcome: amyloid plaque load reduction

Description

Brain tissue from APP/PSEN1/GD3S-/- triple-mutant mice was examined for amyloid-beta plaque formation and associated neuropathology. The analysis included assessment of both aggregated and unaggregated Abeta levels using histological and biochemical methods. Brain sections were processed for amyloid plaque visualization and quantification, comparing plaque burden between triple-mutant mice and APP/PSEN1 control mice. The study revealed that elimination of GD3S resulted in almost complete elimination of Abeta aggregation and associated neurodegeneration, providing neuropathological evidence supporting the behavioral improvements observed in these mice.

TARGET GENE

St8sia1

MODEL SYSTEM

APP/PSEN1/GD3S-/- triple-transgenic mouse brains

ESTIMATED COST

TIMELINE

0 months

PATHWAY

amyloid aggregation and ganglioside interaction pathway

SOURCE

extracted_from_pmid_18258340

PRIMARY OUTCOME

amyloid plaque load reduction

Scoring Dimensions

📖 Wiki Pages

PSEN1 (Redirect)redirect APP Amyloid Pathway in Alzheimer's Diseasemechanism PSEN1-Mutant Neuronscell APP Genegene APP — Amyloid Precursor Proteingene APP→Amyloid-beta→Plaque→Alzheimer's Disease Causalpathway APP Arctic Mutation (APP Arctic)disease APP Dutch Mutation (APP Dutch)disease APP Flemish Mutation (APP Flemish)disease PSEN1 Mutations in Alzheimer's Diseasedisease APP Swedish Mutation (APPswe)mutation APP-Overexpressing Neuronscell PSEN1 — Presenilin 1gene APP Gene Dosage Reduction Therapy for Down Syndromidea APP-BACE1-Fe65 Complexmechanism

Protocol

Establish APP/PSEN1/GD3S-/- triple-transgenic mouse brains cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for St8sia1, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure amyloid plaque load reduction together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting St8sia1 shifts amyloid plaque load reduction in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (amyloid plaque load reduction) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

TREM2-mediated microglial tau clearance enhancement0.594

LRP1-Dependent Tau Uptake Disruption0.576

VCP-Mediated Autophagy Enhancement0.571

Extracellular Vesicle Biogenesis Modulation0.558

HSP90-Tau Disaggregation Complex Enhancement0.551

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.